Synapse Open Synapse
Business

US regulator rejects cancer drug invented in China in blow to Beijing’s biotech sector

Financial Times ·

Summit’s ivonescimab was seen as a test case for whether the country’s medicine could pass scrutiny in the US

Latest from Financial Times